389 Locoregional control and disease specific survival after accelerated hyperfractionated radiotherapy in the treatment of supraglottic carcinoma
Identifieur interne : 00A836 ( Main/Exploration ); précédent : 00A835; suivant : 00A837389 Locoregional control and disease specific survival after accelerated hyperfractionated radiotherapy in the treatment of supraglottic carcinoma
Auteurs : B. M. Nakfoor [États-Unis] ; I. F. Spiro [États-Unis] ; P. Martins [États-Unis] ; F. Effird [États-Unis] ; C. C. Wang [États-Unis]Source :
- European Journal of Cancer [ 0959-8049 ] ; 1995.
English descriptors
- KwdEn :
- Carcinoma, Effective dose, Local control, Local tumour control rates, Multivariate analysis, Neck cancer, Nodal involvement, Overall treatment time, Radiotherapy, Randomized, Regional control, Supraglottic, Supraglottic region, Surgical resection, Total dose, Total treatment time, Treatment delays, Tumour.
- Teeft :
- Carcinoma, Effective dose, Local control, Local tumour control rates, Multivariate analysis, Neck cancer, Nodal involvement, Overall treatment time, Radiotherapy, Randomized, Regional control, Supraglottic, Supraglottic region, Surgical resection, Total dose, Total treatment time, Treatment delays, Tumour.
Abstract
Materials and MethodsThe records of 165 patients undergoing BID radiation for carcinoma of the supraglottis from 19811992 were reviewed. Patients received 66 to 72 Gy in 1.6 Gy bid fractions and received a planned 7 to 14 day break. Median follow-up was 56 months. Fiveyear actuarial local control, regional control and disease-specific survival rates are reported.ResultsFor T1, T2, T3, and T4 tumors, local control was: 95%, 86%, 77% and 42%, respectively (P=0.002), and disease-specific survival was: 79%, 88%, 78%, and 40%, respectively (P=0.0004). For N0, N1, N23 disease, local control was: 86%, 73%, and 54%, respectively (P=0.005), and disease-specific survival was: 86%, 53%, and 54%, respectively (P=0.0001). Regional control by T and N stage was non-significant. With surgical salvage, T1, T2, T3, and T4 ultimate local control was: 95%, 92%, 88%, and 51%, respectively (P=0.001). The laryngeal preservation rate for the entire group was 83% and for T1, T2, T3, and T4 tumors was: 96%, 87%, 78%, and 56%, respectively. Total treatment time greater than 43 days resulted in a decreased local control: 87% versus 70% (P=0.002), and decreased disease-specific survival: 84% versus 69% (P=0.01).ConclusionsAccelerated hyperfractionated radiotherapy resulted in excellent locoregional control, disease-specific survival, and laryngeal preservation rates for T13 and node negative patients. T stage, N stage and total treatment time were predictors of outcome. T4 tumors or node positive neck disease, even N1, portended a poor prognosis, and therefore these patients should be entered into protocols that include adjuvant therapy.
Url:
DOI: 10.1016/0959-8049(95)95642-J
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 005374
- to stream Istex, to step Curation: 005374
- to stream Istex, to step Checkpoint: 004E80
- to stream Main, to step Merge: 00AE46
- to stream Main, to step Curation: 00A836
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">389 Locoregional control and disease specific survival after accelerated hyperfractionated radiotherapy in the treatment of supraglottic carcinoma</title><author><name sortKey="Nakfoor, B M" sort="Nakfoor, B M" uniqKey="Nakfoor B" first="B. M." last="Nakfoor">B. M. Nakfoor</name></author><author><name sortKey="Spiro, I F" sort="Spiro, I F" uniqKey="Spiro I" first="I. F." last="Spiro">I. F. Spiro</name></author><author><name sortKey="Martins, P" sort="Martins, P" uniqKey="Martins P" first="P." last="Martins">P. Martins</name></author><author><name sortKey="Effird, F" sort="Effird, F" uniqKey="Effird F" first="F." last="Effird">F. Effird</name></author><author><name sortKey="Wang, C C" sort="Wang, C C" uniqKey="Wang C" first="C. C." last="Wang">C. C. Wang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A74D5A6301CC067BF6C9875554F2218000FD886F</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0959-8049(95)95642-J</idno><idno type="url">https://api.istex.fr/document/A74D5A6301CC067BF6C9875554F2218000FD886F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">005374</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">005374</idno><idno type="wicri:Area/Istex/Curation">005374</idno><idno type="wicri:Area/Istex/Checkpoint">004E80</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">004E80</idno><idno type="wicri:doubleKey">0959-8049:1995:Nakfoor B:locoregional:control:and</idno><idno type="wicri:Area/Main/Merge">00AE46</idno><idno type="wicri:Area/Main/Curation">00A836</idno><idno type="wicri:Area/Main/Exploration">00A836</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">389 Locoregional control and disease specific survival after accelerated hyperfractionated radiotherapy in the treatment of supraglottic carcinoma</title><author><name sortKey="Nakfoor, B M" sort="Nakfoor, B M" uniqKey="Nakfoor B" first="B. M." last="Nakfoor">B. M. Nakfoor</name><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Mass, General Hospital Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Spiro, I F" sort="Spiro, I F" uniqKey="Spiro I" first="I. F." last="Spiro">I. F. Spiro</name><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Mass, General Hospital Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Martins, P" sort="Martins, P" uniqKey="Martins P" first="P." last="Martins">P. Martins</name><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Mass, General Hospital Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Effird, F" sort="Effird, F" uniqKey="Effird F" first="F." last="Effird">F. Effird</name><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Mass, General Hospital Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Wang, C C" sort="Wang, C C" uniqKey="Wang C" first="C. C." last="Wang">C. C. Wang</name><affiliation wicri:level="2"><country xml:lang="fr" wicri:curation="lc">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Mass, General Hospital Boston, MA 02114</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Cancer</title><title level="j" type="abbrev">EJC</title><idno type="ISSN">0959-8049</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">31</biblScope><biblScope unit="supplement">S6</biblScope><biblScope unit="page" from="S85">S85</biblScope></imprint><idno type="ISSN">0959-8049</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carcinoma</term><term>Effective dose</term><term>Local control</term><term>Local tumour control rates</term><term>Multivariate analysis</term><term>Neck cancer</term><term>Nodal involvement</term><term>Overall treatment time</term><term>Radiotherapy</term><term>Randomized</term><term>Regional control</term><term>Supraglottic</term><term>Supraglottic region</term><term>Surgical resection</term><term>Total dose</term><term>Total treatment time</term><term>Treatment delays</term><term>Tumour</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Carcinoma</term><term>Effective dose</term><term>Local control</term><term>Local tumour control rates</term><term>Multivariate analysis</term><term>Neck cancer</term><term>Nodal involvement</term><term>Overall treatment time</term><term>Radiotherapy</term><term>Randomized</term><term>Regional control</term><term>Supraglottic</term><term>Supraglottic region</term><term>Surgical resection</term><term>Total dose</term><term>Total treatment time</term><term>Treatment delays</term><term>Tumour</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Materials and MethodsThe records of 165 patients undergoing BID radiation for carcinoma of the supraglottis from 19811992 were reviewed. Patients received 66 to 72 Gy in 1.6 Gy bid fractions and received a planned 7 to 14 day break. Median follow-up was 56 months. Fiveyear actuarial local control, regional control and disease-specific survival rates are reported.ResultsFor T1, T2, T3, and T4 tumors, local control was: 95%, 86%, 77% and 42%, respectively (P=0.002), and disease-specific survival was: 79%, 88%, 78%, and 40%, respectively (P=0.0004). For N0, N1, N23 disease, local control was: 86%, 73%, and 54%, respectively (P=0.005), and disease-specific survival was: 86%, 53%, and 54%, respectively (P=0.0001). Regional control by T and N stage was non-significant. With surgical salvage, T1, T2, T3, and T4 ultimate local control was: 95%, 92%, 88%, and 51%, respectively (P=0.001). The laryngeal preservation rate for the entire group was 83% and for T1, T2, T3, and T4 tumors was: 96%, 87%, 78%, and 56%, respectively. Total treatment time greater than 43 days resulted in a decreased local control: 87% versus 70% (P=0.002), and decreased disease-specific survival: 84% versus 69% (P=0.01).ConclusionsAccelerated hyperfractionated radiotherapy resulted in excellent locoregional control, disease-specific survival, and laryngeal preservation rates for T13 and node negative patients. T stage, N stage and total treatment time were predictors of outcome. T4 tumors or node positive neck disease, even N1, portended a poor prognosis, and therefore these patients should be entered into protocols that include adjuvant therapy.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Nakfoor, B M" sort="Nakfoor, B M" uniqKey="Nakfoor B" first="B. M." last="Nakfoor">B. M. Nakfoor</name></region><name sortKey="Effird, F" sort="Effird, F" uniqKey="Effird F" first="F." last="Effird">F. Effird</name><name sortKey="Martins, P" sort="Martins, P" uniqKey="Martins P" first="P." last="Martins">P. Martins</name><name sortKey="Spiro, I F" sort="Spiro, I F" uniqKey="Spiro I" first="I. F." last="Spiro">I. F. Spiro</name><name sortKey="Wang, C C" sort="Wang, C C" uniqKey="Wang C" first="C. C." last="Wang">C. C. Wang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A836 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A836 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A74D5A6301CC067BF6C9875554F2218000FD886F
|texte= 389 Locoregional control and disease specific survival after accelerated hyperfractionated radiotherapy in the treatment of supraglottic carcinoma
}}
| This area was generated with Dilib version V0.6.32. |  |